Astrotech Corporation (Nasdaq: ASTC) reported a 25% decline in research and development expenses in the second quarter of fiscal year 2026. The Company has deployed the TRACER 1000 trace detection system in approximately 35 locations in 16 countries across the United States, Europe, and Asia.

Astrotech’s Chairman and CEO, Thomas B. Pickens III, highlighted positive sales momentum in global markets. The Company’s mass spectrometry and gas chromatography solutions are gaining traction, particularly in the explosives and narcotics trace detection markets. Astrotech has appointed Scott Bartley as Interim CFO and David Spada as Director of Global Sales for 1st Detect subsidiary.

Astrotech Corporation is an instrumentation company with subsidiaries specializing in trace detection systems, process analyzers for agriculture, chemical process control solutions, breath analysis platforms, and environmental GC-MS testing. The Company’s products cater to various markets, including security, industrial manufacturing, and health.

Financially, Astrotech reported a revenue of $148,000 in the second quarter of fiscal year 2026, down from $261,000 in the same period last year. Operating expenses totaled $3,909, resulting in a net loss of $3,927 for the quarter. The Company’s total assets as of December 31, 2025, were $19,696, with liabilities of $4,178 and stockholders’ equity of $15,518.

Read more at GlobeNewswire: Astrotech Reports Second Quarter of Fiscal Year 2026